Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boston Scientific Corporation (NYSE: BSX) files a broad range of reports and disclosures with the U.S. Securities and Exchange Commission, providing detailed insight into its operations as a global medical technology company. These SEC filings cover topics such as financial performance, material acquisitions, executive compensation programs, governance changes and risk factors relevant to the business.
On this page, you can review Boston Scientific’s current reports on Form 8-K, which the company uses to announce material events. Recent 8-K filings describe the definitive agreement to acquire Penumbra, Inc., including references to a joint press release and investor presentation, as well as the adoption of a 2026 annual bonus plan and performance share programs tied to metrics like global sales, adjusted earnings per share, relative total shareholder return and organic net sales growth. Other 8-Ks report quarterly financial results, director retirement plans and changes in senior leadership roles.
In addition to 8-Ks, Boston Scientific’s annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system) include consolidated financial statements, segment and geographic net sales data, discussions of MedSurg and Cardiovascular businesses, and extensive risk factor sections. These filings also explain the company’s use of non-GAAP financial measures such as operational and organic net sales growth and adjusted earnings per share, with reconciliations to GAAP figures.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify information on acquisitions, compensation plans, performance metrics and risk disclosures. Real-time updates from EDGAR ensure that new Boston Scientific filings, including Forms 10-K, 10-Q and 4 (insider transaction reports), are added as they become available, while AI-generated explanations assist in interpreting complex financial and legal language.
Boston Scientific Corp. (BSX) filed a Form 144 indicating a proposed sale of 2,901 common shares through Morgan Stanley Smith Barney on or after 07/29/2025. The block is valued at approximately $310,378, based on the filing’s stated aggregate market value. The shares represent an immaterial 0.0002 % of BSX’s 1.48 billion shares outstanding.
The shares were acquired as restricted stock on 05/01/2025. No other sales by the filer have occurred in the past three months, and the notice affirms the absence of undisclosed material adverse information. A Form 144 is a routine regulatory notice and does not itself execute a sale; it merely provides advance disclosure of an intent to sell restricted or control securities under Rule 144.
Given the modest dollar amount and tiny percentage of float, the transaction is unlikely to be material to Boston Scientific’s capital structure or market liquidity. Investors typically monitor such filings for insider-sentiment cues, but under Rule 144 the filer must still comply with volume, manner-of-sale, and holding-period restrictions before selling.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
